Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate treatment for multiple solid tumors, carries risk of interstitial lung disease/pneumonitis (ILD). Management guidelines generally mandate interrupting T-DXd treatment for grade 1 ILD, with possible retreatment following resolution of imaging findings. This pooled analysis examined T-DXd retreatment duration and ILD recurrence following recovery from grade 1 ILD.
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Annals of Oncology | | H.S. Rugo, E. Tokunaga, H. Iwata, V. Petry, E.F. Smit, Y. Goto, D.-W. Kim, K. Shitara, J.F. Gruden, S. Modi, J. Cortés, I. Krop, P.A. Jänne, Y. Cheng, C. Taitt, F.-C. Cheng, C.A. Powell
Topics: blood-cancer, targeted-therapy, new-technology, research